OR WAIT null SECS
January 06, 2016
The Cell Therapy Catapult, University of Birmingham, and Cancer Research Technology collaborate on CAR-T cell immuno-oncology therapy development.
December 17, 2015
Synpromics announced collaborations with Avalanche Biotechnologies and Applied Genetic Technologies Corporation to use synthetic promoters to develop gene therapies, including adeno-associated virus technology for treating eye diseases.
December 04, 2015
Adaptimmune Therapeutics and Universal Cells enter into collaboration and license agreement to develop universal allogeneic T-cell therapies.
November 13, 2015
High-dose axalimogene filolisbac immunotherapy will advance to expansion phase.
October 23, 2015
Melanoma treatment, Imlygic, received a positive opinion from CHMP, and several other products received extension of indications.
October 22, 2015
AstraZeneca and Lilly will evaluate the safety and efficacy of a range of additional combinations for solid tumors across both companies’ complementary portfolios.
October 13, 2015
Cell Therapy Catapult will provide manufacturing scale-up services to enable Asterias’ future clinical trials and commercial supply for Asterias’ allogeneic dendritic cell immunotherapy, AST-VAC2.
Biogen, Sobi, and the World Federation of Hemophilia collaborated to enable a sustained humanitarian supply of hemophilia treatment to developing countries, and the first shipments have begun to arrive.
October 07, 2015
The Cell History File is designed as a “cell passport” for developers and manufacturers of tissue- and cell-based medicinal products.
September 29, 2015
The results from an international study on nivolumumab, published in the New England Journal of Medicine, suggest a paradigm shift in the standard of care for previously treated lung cancer patients.